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Spectrum of Activity and Mechanisms of Resistance of Various
Nucleoside Derivatives against Gammaherpesviruses
Natacha Coen, Sophie Duraffour, Dimitri Topalis, Robert Snoeck, Graciela Andrei
Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
The susceptibilities of gammaherpesviruses, including Epstein-Barr virus (EBV), Kaposi’s sarcoma-associated herpesvirus
(KSHV), and animal rhadinoviruses, to various nucleoside analogs was investigated in this work. Besides examining the antiviral
activities and modes of action of antivirals currently marketed for the treatment of alpha- and/or betaherpesvirus infections (in-
cluding acyclovir, ganciclovir, penciclovir, foscarnet, and brivudin), we also investigated the structure-activity relationship of
various 5-substituted uridine and cytidine molecules. The antiviral efficacy of nucleoside derivatives bearing substitutions at the
5 position was decreased if the bromovinyl was replaced by chlorovinyl. 1--D-Arabinofuranosyl-(E)-5-(2-bromovinyl)uracil
(BVaraU), a nucleoside with an arabinose configuration of the sugar ring, exhibited no inhibitory effect against rhadinoviruses
but was active against EBV. On the other hand, the fluoroarabinose cytidine analog 2=-fluoro-5-iodo-aracytosine (FIAC) showed
high selectivity indices against gammaherpesviruses that were comparable to those of brivudin. Additionally, we selected brivu-
din- and acyclovir-resistant rhadinoviruses in vitro and characterized them by phenotypic and genotypic (i.e., sequencing of the
viral thymidine kinase, protein kinase, and DNA polymerase) analysis. Here, we reveal key amino acids in these enzymes that
play an important role in substrate recognition. Our data on drug susceptibility profiles of the different animal gammaherpesvi-
rus mutants highlighted cross-resistance patterns and indicated that pyrimidine nucleoside derivatives are phosphorylated by
the viral thymidine kinase and purine nucleosides are preferentially activated by the gammaherpesvirus protein kinase.
The gammaherpesvirus subfamily includes two major genera,the lymphocryptovirus and rhadinovirus, of which the human
tumor viruses Epstein-Barr virus (EBV) and Kaposi’s sarcoma-
associated herpesvirus (KSHV), respectively, are the best-charac-
terized members (1). A hallmark of these human herpesviruses is
that they do not easily replicate in primary infection in cells in
culture (2). In contrast, other members of the rhadinovirus
genus, murine gammaherpesvirus 68 (MHV-68), herpesvirus
saimiri (HVS), and rhesus rhadinovirus (RRV), are able to rep-
licate to high titers in cell culture, and thus, they may serve as
model systems for human gammaherpesviruses in experimen-
tal settings (3).
Overall, antiherpesvirus therapies are aimed at selectively in-
hibiting the lytic replication of the virus. At present, the antiviral
agents used in EBV and KSHV viral infections are those that are
approved for the treatment of other herpesvirus infections (4), in
particular ganciclovir (GCV) for both EBV and KSHV and also
acyclovir (ACV) in the case of EBV. Other structurally related
antiherpetics that are currently marketed, such as penciclovir
(PCV) and brivudin (BVDU), have also been evaluated in vitro
against EBV and KSHV replication (5–8) but have not been used
in the clinic. Differences in antiviral activities of GCV, ACV, PCV,
and BVDU against EBV and KSHV in vitro have been well de-
scribed. These nucleosides selectively inhibit EBV replication in
vitro, whereas the antiviral activity of ACV and PCV against KSHV
proved to be very weak (5–13). Acyclic or carbocyclic guanos-
ine analogs have also been studied in the context of inhibiting
EBV replication, and they include in particular H2G (omaci-
clovir), A-5021 [(1S=,2R=)-9-[[1=,2=-bis(hydroxymethyl)cyclo-
prop-1-yl]methyl]guanine] and S2242 [2-amino-7-[1,3-dihy-
droxy-2-propoxymethyl)purine] (14–16).
To become biologically active, nucleoside analogs must first be
phosphorylated to their active triphosphate forms to inhibit the
viral DNA polymerase and/or to be incorporated into the viral
DNA. The initial phosphorylation of nucleosides to their mono-
phosphate form is carried out by viral kinases. ACV, GCV, PCV,
and BVDU are converted to their monophosphate form by the
viral thymidine kinase (TK) in alphaherpesvirus-infected cells. In
contrast to ACV (which is not recognized by cellular nucleoside
kinases), GCV is converted to its monophosphate form at low
levels by cellular kinases. This may contribute to the difference in
toxicity between the two drugs. Although the EBV and KSHV TKs
are able to phosphorylate nucleoside analogs of thymidine, such as
BVDU and azidodeoxythymidine, these enzymes appear to be in-
efficient at catalyzing the phosphorylation of ACV and GCV (17–
19). This feature highlights the more restricted substrate specific-
ity of the EBV and KSHV TKs compared to the TKs of herpes
simplex virus (HSV) and varicella-zoster virus (VZV) (17–19). In
regard to the phosphorylation of ACV and GCV by the gamma-
herpesvirus TK, different groups have reported conflicting find-
ings. Some researchers have suggested that gammaherpesvirus TK
is not able to phosphorylate ACV and GCV, while others have
demonstrated that this enzyme does possess some activity toward
these nucleosides (17, 18, 20–22). Nevertheless, there is a general
agreement that ACV and GCV are phosphorylated to their mono-
phosphate form by the viral protein kinase (PK) in gammaherpes-
virus-infected cells (20, 21). The gammaherpesvirus protein ki-
nase is the homolog of the human cytomegalovirus (HCMV) (a
betaherpesvirus) protein kinase pUL97, which phosphorylates
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GCV and to a lesser extent ACV to their monophosphate forms in
HCMV-infected cells (23).
The benzimidazole derivative maribavir (MBV) is a potent in-
hibitor of HCMV and EBV replication (24), but unlike the case
with nucleoside analogs, its activity is not dependent on phos-
phorylation and this compound does not target the viral DNA
polymerase. Instead, MBV directly inhibits pUL97 of HCMV, af-
fecting viral assembly and nuclear egress (25). MBV also inhibits
EBV replication, but the mechanism of action of MBV against the
EBV lytic phase is more complex than that for HCMV. This may
be linked to the indirect effects of MBV on the transcription of
EBV genes through the interaction of EBV PK with multiple viral
proteins (24, 26).
Drug-resistant HSV, VZV, and HCMV are found relatively
frequently in the clinic, almost exclusively among severely immu-
nocompromised patients receiving prolonged antiviral therapy,
mainly ACV or GCV (27). Viral mutations conferring resistance
to nucleoside analogs have been found in either the drug-activat-
ing genes, i.e., HSV TK, VZV TK, or HCMV UL97 gene, and/or in
conserved regions of the viral DNA polymerase (27). In the ma-
jority of cases, the mechanism underlying resistance to ACV in
HSV is TK deficiency (TK) as a result of a deletion(s), inser-
tion(s), or point mutation(s) in the encoding gene. Mutations in
HSV TK occur preferentially at a limited number of hot spots
within long homopolymer nucleotide stretches, rather than being
randomly distributed throughout the gene (28).
Since GCV is the drug of choice for prophylactic and preemp-
tive HCMV therapy, resistance mutations are detected most fre-
quently (90%) in the UL97 gene, consistently in a limited num-
ber of codons (27, 29). Additionally, there is a larger number of
different mutations in the DNA polymerase, which tend to be
selected only after extended periods of HCMV treatment with
GCV (29). Interestingly, mutations in the UL97 gene associated
with resistance to GCV or MBV do not overlap, since MBV-asso-
ciated mutations occur upstream of known GCV resistance mu-
tations (30).
In contrast, no drug-resistant EBV and KSHV strains have ever
been isolated from patients, though monitoring the development
of resistance might be useful, especially when immunocompro-
mised hosts with EBV or KSHV diseases are treated with antiviral
agents (31). In addition, no studies have reported the in vitro se-
lection and characterization of drug-resistant EBV and KSHV
strains, while this has been extensively investigated for other her-
pesviruses, such as HSV, VZV, and HCMV. Yet structure-func-
tion studies concerning the EBV and KSHV TKs have been de-
scribed. This has been achieved by the engineering of different
viral TK mutants by site-directed mutagenesis in order to charac-
terize essential residues in the conserved ATP and substrate bind-
ing site of the EBV TK (32, 33) and investigate the contributions of
the N- and C-terminal regions of KSHV TK (34).
In this report, we evaluate the inhibitory activities of various
nucleoside analogs against EBV, KSHV, MHV-68, HVS, and RRV.
Since the currently established in vitro assays for EBV and KSHV
do not allow efficient selection of drug-resistant viruses, cell cul-
ture systems with HVS and MHV-68 were used to select and char-
acterize gammaherpesvirus mutants resistant to BVDU and ACV.
Hence, we identified amino acids that are important for drug in-
teractions within the gammaherpesvirus TK, PK, and DNA poly-
merase and defined the patterns of cross-resistance of the different
in vitro-selected mutant viruses.
MATERIALS AND METHODS
Cell culture and viruses. KSHV-infected BCBL-1 cells (NIH AIDS Re-
search and Reference Reagent Program) and EBV-infected P3HR-1 cells
(ATCC HTB-62) were cultured in RPMI 1640 medium (Life Technologies
Europe BV, Ghent, Belgium). Murine fibroblasts (NIH 3T3 cells; ATCC
CRL-1685), owl monkey kidney cells (OMK) (ATCC CRL-1556), and
rhesus monkey fibroblasts (RF) (kindly provided by S. Wong, Oregon
Health and Science University, Beaverton, OR, USA) were grown in Dul-
becco’s modified eagle’s medium (DMEM). All media were supplemented
with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 1%
nonessential amino acids, 1% sodium pyruvate, and 1% HEPES. Cultures
were incubated at 37°C and 5% CO2. The following viral strains were used:
MHV-68 (clone G2.4; provided by A. A. Nash, Edinburgh, United King-
dom), HVS (strain C-488; ATCC VR-1414), and RRV (strain 17577;
kindly provided by S. Wong, Oregon Health and Science University, Bea-
verton, OR, USA) and were grown, respectively, in NIH 3T3, OMK, and
RF cells.
Compounds. The sources of the compounds that were used in this
study are presented in Table 1.
Antiviral assays. The drug susceptibility profiles of MHV-68, HVS,
and RRV were evaluated by cytopathic effect (CPE)-reduction assays in
their corresponding cell lines in 96-well plates as described previously
(35). Briefly, after virus absorption for 2 h at 37°C, compounds diluted in
fresh medium were added to the virus-infected cells. Viral CPE was re-
corded microscopically based on detectable alterations of the cell mor-
phology as soon as it reached completion in the untreated, virus-infected
cells. The scale used for scoring the CPE was as follows: (0, 0% CPE, 1,
20% CPE; 2, 20 to 40% CPE; 3,40 to 60% CPE; 4, 60 to 80%; 5, 80 to
100% CPE. The antiviral activity was expressed as the EC50, the concen-
tration required to reduce virus-induced CPE by 50% compared to the
untreated controls, and was estimated from graphic plots. The antiviral
assays for KSHV and EBV were performed in 48-well plates. Viral repli-
cation was induced in BCBL-1 and P3HR-1 cells by adding 20 ng/ml
12-O-tetradecanoylphorbol 13-acetate (TPA) (Sigma-Aldrich, Bornem,
Belgium) to the growing cells in the presence or absence of the test com-
pounds. After 5 days, the intracellular DNA was quantified by real-time
quantitative PCR (qPCR). Forward and reverse primers, as well as Taq-
Man probe sequences, allowing the detection of the target ORF73 gene of
KSHV and BNRF1 gene of EBV have been described elsewhere (35).
The cytostatic effects of the compounds were determined based on the
inhibition of cell growth for NIH 3T3, OMK, RF, uninduced BCBL-1, and
P3HR-1 cells, as previously described (35). The number of cells was de-
termined using a Coulter counter, and the cytostatic concentration was
calculated as the CC50, or the concentration of the compound required to
reduce cell growth by 50% relative to the number of cells in the untreated
controls.
Selection of drug-resistant viruses. Drug-resistant HVS and MHV-68
were obtained by serial passages of the virus in the presence of increasing
concentrations of BVDU or ACV, starting at a concentration equivalent to
their EC50. OMK and NIH 3T3 cells were seeded in 25-cm
2 flasks and
infected with HVS (C488) or MHV-68 (G2.4) in the presence of the drug.
When full CPE was reached, samples were frozen and virus was harvested
and used to infect cells for the next passage. This process was repeated
several times in increasing concentrations of the compound. After 12
(ACV) and 13 (BVDU) passages, several HVS resistant clones were iso-
lated by limiting dilution. Drug-resistant MHV-68 clones were selected
after 13 (ACV) and 27 (BVDU) passages. All viral clones were tested for
their drug sensitivity by measuring the EC50s in CPE reduction assays. The
TK, PK, and DNA polymerase of each drug-resistant clone was sequenced.
The level of drug resistance (fold-resistance) was expressed as the ratio of
the EC50 of the resistant virus to the EC50 of wild-type (WT) virus.
Sequence analysis. DNA of drug-resistant HVS or MHV-68 clones
was extracted (Qiagen), and the viral TK, PK, and DNA polymerase were
amplified by PCR using FastStart high-fidelity DNA polymerase (Roche
Applied Science, Mannheim, Germany). PCR was performed, following
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the manufacturer’s instructions. The PCR products were purified using
the QIAquick purification kit (Qiagen), and gene amplicons were directly
sequenced using the cycle sequencing kit BigDye Terminator kit, version
3.1, on an ABI 3730 sequencing system (Applied Biosystems) and a set of
primers spanning the entire coding region of the genes. The sequencing
results were computer assembled and compared with the sequence from
the WT gene using the software program SeqScape version 2.7 (Applied
Biosystems).
RESULTS
Activities and selectivities of nucleoside analogs. The antiviral
efficacies and selectivities of structurally related compounds
against different gammaherpesviruses were determined, and the
results are summarized in Table 2; their chemical structures are
shown in Fig. 1. The guanosine analogs ACV, PCV, GCV, and
H2G showed marked inhibitory activities against EBV replication
(EC50 of approximately 4.5 M for ACV, PCV, and GCV and 7.5
M for H2G). In contrast, rhadinoviruses (i.e., KSHV, MHV-68,
HVS, and RRV) were moderately sensitive to GCV (EC50s ranging
from 11 M to 82 M) and weakly sensitive to ACV and PCV
(EC50s 100M), with the exception of the inhibitory activity of
ACV against MHV-68 (EC50 of 9 M). H2G did not inhibit
KSHV, HVS, and RRV replication at the highest concentration
evaluated, while a weak activity was measured against MHV-68
(EC50 of 59 M).
All gammaherpesviruses tested were sensitive to the inhibitory
effects of BVDU, with EC50s of 0.09 M (MHV-68), 0.3 M
(RRV), 0.6M (KSHV), 2.4M (EBV). and 5.7M (HVS). Also,
5-(2-chlorovinyl)-2=-deoxyuridine (CVDU) and (E)-5-(2-chlo-
rovinyl)-2=-deoxycytidine [(E)-CVDC] had substantial inhibi-
tory effects against gammaherpesviruses, with the exception of
(E)-CVDC against HVS (EC50 of 122 M). BTDU, particularly
active against VZV (36) and HSV (37), did not show any activity
against gammaherpesviruses. 5-Iodo-2=-deoxyuridine (IDU)
showed high inhibitory effects against MHV-68 replication, with
an EC50 of 0.8 M, and also possessed some activity against EBV
(EC50 of 10 M). In contrast, 5-ethyl-2=-deoxyuridine (EDU)
showed weak antiviral activity against both MHV-68 and EBV
(EC50 of 43 M and 74 M, respectively).
Unlike BVDU, its arabinofuranosyl counterpart {i.e.,
BVaraU [(E)-5-(2-bromovinyl)-1--D-arabino-pentafurano-
syluracil]} showed only inhibitory effects against EBV replica-
tion (EC50 of 11 M) but not against rhadinoviruses. The ara-
binofuranosyl adenosine analog AraA possessed low antiviral
activity against EBV, KSHV, HVS and RRV, whereas MHV-68
replication was inhibited at an EC50 of 2 M. The fluoroarabi-
nose cytidine analog 2=-fluoro-5-iodo-aracytosine (FIAC)
showed pronounced antiviral activity against all gammaher-
pesvirus tested, with EC50 of 2.4 M.
Guanosine analogs had no cytostatic activity, but IDU and to a
lesser extent FIAC and AraA showed the highest cytostatic effects
on human lymphoblastoid cells (P3HR-1 and BCBL-1), murine
fibroblasts (NIH 3T3), and simian epithelial cells (OMK). The
molecules EDU and BVDU showed moderate cytostatic effects on
NIH 3T3 cells, with CC50s of 17 M and 18 M, respectively.
Weak or no toxicity was seen for the other drugs, since the CC50
values were 100 M. All tested nucleoside analogs showed no
noticeable cytostatic effects on RF cells.
The selectivity indices (SIs) were determined for each of the
compounds. GCV, BVDU, CVDU, (E)-CVDC, and FIAC showed
high selectivity against the majority of the gammaherpesviruses.
Furthermore, high SI values were calculated against EBV for the
following compounds in decreasing order of SIs: ACV (SI of 228),
TABLE 1 Description and source of the compounds used in this study
Group
Compound(s)
(abbreviation) Description Source
Nucleoside analogs Acyclovir (ACV) 9-(2-Hydroxyethoxymethyl)guanine GlaxoSmithKline, Stevenage, UK
Ganciclovir (GCV) 9-(1,3-Dihydroxy-2-propoxymethyl)guanine Roche, Basel, Switzerland
Penciclovir (PCV) 9-(4-Hydroxy-3-hydroxymethylbut-1-yl)guanine Aventis, Frankfurt, Germany
Brivudin (BVDU) E-5-(2-bromovinyl)-2=-deoxyuridine Searle, UK
BVaraU (E)-5-(2-bromovinyl)-1--D-arabino-pentafuranosyluracil Soy sauce; Yamasa, Koshi, Japan
BTDU 5-(5-Bromo-2-thienyl)-2=-deoxyuridine Rega Institute for Medical Research,
Leuven, Belgium
IDU 5-Iodo-2=-deoxyuridine Sigma Chemicals, St. Louis, MO
EDU 5-Ethyl-2=-deoxyuridine Sigma Chemicals, St. Louis, MO
(E)-CVDC (E)-5-(2-chlorovinyl)-2=-deoxycytidine A. Kumar, Department of
Chemistry, Uttar Pradesh, India
CVDU 5-(2-Chlorovinyl)-2=-deoxyuridine University of Birmingham,
Birmingham, UK
FIAC 2=-Fluoro-5-iodo-aracytosine Bristol-Myers Company, Research
Parkway, Wallingford, CT
Omaciclovir
(H2G)
(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine Wellcome Research Laboratories,
Kent, UK
Vidarabine (AraA) 9--D-Arabinofuranosyladenine Sigma Chemicals, St. Louis, MO
Pyrophosphate analog Foscarnet (PFA) Phosphonoformate sodium salt Sigma Chemicals, St. Louis, MO
Acyclic nucleoside
phosphonates
Cidofovir
(HPMPC)
(S)-1-[3-hydroxy-2-(phosphonomethoxypropyl) cytosine] Gilead Sciences, Foster City, CA
Adefovir (PMEA) 9-[2- (Phosphonomethoxyethyl)adenine] Gilead Sciences, Foster City, CA
HPMPA (S)-9-[3-hydroxy-2- (phosphonomethoxy)-propyl]adenine Marcela Krecmerova, Institute of
Organic Chemistry and
Biochemistry, Academy of
Sciences of the Czech Republic,
Prague, Czech Republic
HPMPO-DAPy (R)-[2,4-diamino-3-hydroxy-6-[2-(phosphonomethoxy)propoxy]]pyrimidine M. Krecmerova
HPMP-5-azaC 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine M. Krecmerova
PMEADAP 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine M. Krecmerova
PMEAO-DAPy 2,4-Diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine M. Krecmerova
Coen et al.
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PCV (SI of 149), BVaraU (SI of 45), and H2G (SI of 27).
Moderate drug selectivity was also observed for EDU against EBV
(SI of 8) and for ACV and IDU against MHV-68, with SIs of 11 and
9, respectively.
Isolation of HVS and MHV-68 strains resistant to BVDU and
ACV. HVS and MHV-68 were cultured for several passages in the
presence of the antiviral agent BVDU or ACV. Of note, PCV was
not included in these studies, since this compound only weakly
inhibited HVS and MHV-68 replication (EC50 of 367M and 115
M, respectively) (Table 2). Viral stocks of HVS and MHV-68
were prepared when the viruses were able to grow at a concentra-
tion of 200 to 400M of the compounds. When these viral stocks
displayed resistance (i.e., increases in EC50s) to the drug of inter-
est, viral clones were subsequently isolated by limiting dilution.
These clones were used in all genotyping and phenotyping assays.
The viral TK, PK, and DNA polymerase genes were sequenced
to map eventual drug-associated mutations, since the encoded
proteins are known to be involved in the activation of these mol-
ecules or as the target of the activated drugs (Table 3).
After 13 passages of HVS under pressure of BVDU, four clonal
populations bearing mutations in the TK gene were found (Table
3). In contrast, the sequences of the PK and DNA polymerase
genes were identical to those for the WT viruses. Two HVS
BVDU-resistant (BVDUr) clones harbored a mutation that re-
sulted in the introduction of a stop codon at the N-terminal region
of the viral TK (R45stop). In two other clones, this mutation was
associated with another mutation, localized at the C-terminal re-
gion of the viral TK, that also led to the appearance of the stop
codon E364stop. One HVS BVDUr clone had an amino acid sub-
stitution changing the alanine residue to an aspartic acid at codon
398 of the TK (A398D). The A398D change appeared also in com-
bination with the R45stop change (Table 3).
Genotyping of HVS clones grown under pressure of ACV re-
vealed the presence of mutations in the viral DNA polymerase and
PK genes and not in TK gene. Two populations were identified.
The first population harbored a substitution in the viral DNA
polymerase, S529Y, together with a frameshift insertion in the PK,
which was due to an insertion of one thymidine at nucleotides
1016 and 1017. The second population had a single amino acid
substitution L631I in the viral DNA polymerase.
After 27 passages of MHV-68 in the presence of BVDU, the
four isolated clones harbored one single amino acid substitution,
C372W, in the viral TK. Both the PK and DNA polymerase genes
had sequences identical to that of the WT.
Selection of ACVr MHV-68 mutants resulted in the identification
of a frameshift deletion in the PK and not in the TK and DNA poly-
merase. It consisted of a deletion of two nucleotides (GT) at positions
1175 and 1176 in the C-terminal region of the viral PK gene.
Drug susceptibility profiles of BVDUr and ACVr gammaher-
pesvirus clones. Phenotypic studies were performed for all drug-
resistant HVS and MHV-68 clones listed in Table 3. Their sensi-
tivities to the nucleoside analogs BVDU, ACV, and GCV, to the
acyclic nucleoside phosphonates (HPMPC, HPMP-5-azaC,
HPMPA, HPMPO-DAPy, PMEA, and PMEDAP), and to the py-
rophosphate analog phosphonoformate sodium (PFA) were de-
termined (Fig. 2 and 3). For each compound, the EC50 of the
mutant virus was compared with the EC50 of WT virus, and the
result is referred to as the fold -resistance at the tops of graphs.
All HVS clones selected under pressure of BVDU harboring
mutations in the viral TK gene were highly resistant to BVDU
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(fold resistance of 171) (Fig. 2). Their sensitivities to the other
nucleoside analogs (i.e., ACV and GCV), to acyclic nucleoside
phosphonates, and to PFA was not altered.
The HVS DNA polymerase L631I substitution (obtained un-
der ACV pressure) conferred resistance not only to ACV (5-
fold) but also to GCV and to HPMPC, HPMP-5-azaC, PMEA,
PMEDAP, and PFA. The highest levels of cross-resistance were
seen for HPMPC and HPMP-5-azaC (7- and 8-fold, respectively).
The ACVr HVS strain that harbored mutations in the viral DNA
polymerase and in the PK showed a similar drug resistance profile,
a5-fold resistance to ACV and GCV, and with resistance levels
to HPMPC, HPMP-5-azaC, PMEA, PMEDAP, and PFA varying
from 5- to 6-fold. Both HVS strains were still sensitive to the
inhibitory effects of BVDU, HPMPA, and HPMPO-DAPy.
FIG 1 Chemical structures of BVDU and analogs, AraA, FIAC, and H2G.
TABLE 3 Identification of mutations in drug-resistant HVS and MHV-68
Virus Compound (na)
No. of
clones/total Viral geneb Nucleotide change(s)c Amino acid change(s)
HVS BVDU (13) 2/6 TK C133T R45stop
2/6 TK C133T	 G1090T R45stop	 E364stop
1/6 TK C1193A A398D
1/6 TK C133T	 C1193A R45stop	 A398D
ACV (12) 1/3 DNA polymerase C1586A S529Y
PK T insertion at nt 1016–1017 Frameshift
2/3 DNA polymerase C1891A L631I
MHV-68 BVDU (27) 4/4 TK T1116G C372W
ACV (13) 3/3 PK GT deletion of nt 1175–1176 Frameshift
a n, number of passages of the virus in cell culture in the presence of increasing concentrations of the compound.
b The viral TK, PK, and DNA polymerase genes were sequenced for all clones. TK, thymidine kinase; PK, protein kinase.
c nt, nucleotides.
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As shown in Fig. 3, the BVDUr MHV-68 clones bearing the
C372W substitution had a mean EC50 for BVDU increased by
19-fold compared to that of the WT strain, while their sensitivities
to the other evaluated drugs did not change. The MHV-68 ACVr
clones that harbored a frameshift deletion in the viral PK were
resistant to ACV (13-fold increase in EC50) and GCV (5-fold in-
crease in EC50) and remained sensitive to BVDU. Similarly to the
BVDUr clones, these mutants were inhibited by different acyclic
nucleoside phosphonates and PFA.
Cross-resistance of drug-resistant TK and PK mutants to a
selection of nucleoside derivatives. We further evaluated the sen-
sitivities of three drug-resistant viral strains, i.e., an HVS TK
mutant (R45stop, BVDUr), an MHV-68 TK mutant (C372W,
BVDUr), and an MHV-68 PK mutant (GT deletion at nucleotides
1175 to 1176, ACVr), to a selection of nucleoside analogs, which
are presented in Table 1 [i.e., IDU, EDU, (E)-CVDC, FIAC, H2G,
and AraA]. Additionally, we included in this study an MHV-68
TK mutant, previously selected in our laboratory, which harbored
FIG 2 The susceptibilities of BVDUr and ACVr HVS clones to nucleoside analogs, acyclic nucleoside phosphonates, and PFA. The data are presented as dot plots
of the EC50 (M) for the drug-resistant clones versus the EC50 for the wild-type (WT) virus. The fold resistance (ratio of EC50 for mutant virus to EC50 for WT
virus) was calculated and is shown at the top of each graph. Note that when a value is not given, the ratio was equal to 1. EC50s were determined by CPE reduction
assays, and horizontal bars indicate the mean values for one representative clone tested in three independent experiments.
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an insertion of one cytosine at nucleotides 661 to 665 in the N-ter-
minal region of the TK, resulting in a frameshift (MHV-68 TK C
insertion at nucleotides 661 to 665). The latter was selected under
pressure of the thiothymidine derivative KAH-39-149 (38). While
an MHV-68 PK mutant was included in this study, we were unable
to include an HVS PK mutant since none has been selected yet.
Figure 4 depicts the fold resistance profiles of these four HVS
and MHV-68 mutants toward six nucleoside derivatives. The
three HVS and MHV-68 TK mutants showed resistance to the
pyrimidine analogs IDU, EDU, and (E)-CVDC, with levels of re-
sistance ranging from4 to52. A 2- to 4-fold resistance to FIAC
was seen for mutants encoding a truncated TK (R45stop and C
insertion at nucleotides 661 to 665), while the presence of the
C372W substitution in MHV-68 TK did not confer cross-resis-
tance to FIAC. Also, a C insertion at nucleotides 661 to 665 in
MHV-68 TK conferred higher levels of resistance against IDU and
EDU than the C372W substitution.
While the purine derivative H2G remained active against TK
MHV-68 mutants, it showed decreased inhibitory effects against
the MHV-68 PK mutant, since a 6-fold increase in mean EC50over
that of the WT virus was observed. H2G was not evaluated against
the HVS TK mutant virus, since the drug does not possess antiviral
activity against WT HVS. The four mutant gammaherpesviruses
did not show altered sensitivity to AraA.
DISCUSSION
The selectivity of nucleoside analogs against herpesviruses is de-
termined by the ability and efficiency of viral kinases (i.e., TK
and/or PK) to catalyze the first phosphorylation step in drug acti-
vation compared to that of cellular kinases (4, 23, 39). Whereas
HSV-1 and VZV TKs are able to convert ACV, GCV, PCV, and
BVDU to their monophosphate forms, gammaherpesvirus TK
substrate specificity is narrow, and it preferentially phosphoryl-
ates pyrimidine derivatives, such as BVDU. Similar to the case
with HCMV, EBV and KSHV PKs are the viral enzymes that phos-
phorylate the guanosine analogs ACV and GCV (17, 18, 20, 21).
This study highlighted the difference in antiviral activities of
various nucleoside analogs against EBV on the one hand and dis-
crepancies in the spectra of activity among rhadinoviruses on the
other hand. While ACV, PCV, GCV, and H2G were active against
EBV, the sensitivities of rhadinoviruses (KSHV, MHV-68, HVS,
and RRV) to these guanosine analogs drugs were markedly re-
duced, in particular for ACV (except for MHV-68), PCV, and
H2G. These results suggested a low affinity of guanosine analogs
for KSHV, HVS, and RRV PKs, in contrast to the case with EBV
PK and to a lesser extent MHV-68 PK. Yet this hypothesis needs to
be further investigated in enzymatic studies using purified gam-
maherpesvirus PKs. Notably, ACV showed high activity against
MHV-68 (EC50 of 9 M), indicating that MHV-68 PK could be
functionally more related to EBV PK than to KSHV, HVS, or RRV
PKs, although sequence identity of the PKs is similar (approxi-
mately 23%) between gammaherpesviruses.
The antiviral tests showed the high activity of H2G against EBV
and to a lesser extent against MHV-68 replication, whereas no
activity was observed against KSHV, HVS, and RRV. These data
further support the assumption made above, that MHV-68 PK
functionally more closely resembles EBV PK, and H2G may be a
substrate of MHV-68 PK. Indeed, results obtained from the phe-
notypic assays with the MHV-68 PK mutant (GT deletion at nu-
cleotides 1175 to 1176) demonstrated that this mutation con-
ferred cross-resistance to H2G and to ACV and GCV, whereas
such a drug-resistant phenotype was not observed with the
FIG 3 Susceptibilities of BVDUr and ACVr MHV-68 clones to nucleoside analogs, acyclic nucleoside phosphonates, and PFA. The data are presented as dot plots
of the EC50 (M) for the drug-resistant clones versus the EC50 for the wild-type (WT) clones. If the fold resistance (ratio of EC50 for mutant virus to EC50 for WT
virus) was1, the value of the ratio of EC50 for the mutant to EC50 for the WT is indicated at the top of the graph. EC50s were determined by CPE reduction assays,
and horizontal bars indicate the mean values for a representative clone tested in three independent experiments.
FIG 4 Levels of drug resistance of HVS and MHV-68 clones bearing a muta-
tion in the viral thymidine kinase (TK) or protein kinase (PK). The data are
presented as the fold changes in EC50s (EC50 for mutant virus to EC50 of
wild-type virus). The fold resistance is given in log scale to facilitate compari-
son of drug resistance levels, which is given by a ratio 2.
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MHV-68 TK-deficient (C insertion at nucleotides 661 to 665) or
TK C372W mutant. This strongly supports that MHV-68 PK is
partially responsible for the antiviral activity of H2G in vitro.
However, Lowe and colleagues observed that the EBV TK was able
to phosphorylate H2G to the monophosphate form in enzymatic
studies, yet this enzyme was only partially purified (40). In fact, we
may speculate that EBV TK is able to recognize and phosphorylate
H2G but that the viral PK is the predominant kinase that activates
the drug in vivo, which would be analogous to what is seen with
GCV (20, 21).
H2G triphosphate has been shown to possess a longer intracel-
lular half-life than its structural analog ACV (40), and similar to
the case with ACV, H2G has an orally bioavailable prodrug, i.e.,
valomaciclovir (41). Valomaciclovir has been evaluated in clinical
trials for the treatment of zoster (phase IIb) (41, 42) and for the
treatment of acute infectious mononucleosis (phase I/II), which
have been successfully completed (clinicaltrials.gov identifier
NCT00575185). In the oral compartment of 11 individuals with
infectious mononucleosis treated with valomaciclovir (4 g/day for
21 days), the mean EBV load was significantly reduced versus that
with a placebo (43).
Unlike the other purine nucleoside derivatives tested in this
report, AraA is known to be phosphorylated to its active triphos-
phate form by cellular kinases and is not dependent for its activa-
tion on viral kinases (44). Hence, no alterations in antiviral activ-
ity of AraA were seen for the MHV-68 PK mutant or for the HVS
and MHV-68 TK mutant strains in this study.
The cross-resistance study performed using HVS and MHV-68
TK mutants revealed that uridine derivatives (BVDU, IDU, and
EDU), as well as cytosine derivatives [(E)-CDVC and FIAC], de-
pend on gammaherpesvirus TK for their activation. However,
these compounds might have different affinities for the viral TKs,
since the inhibitory activities differed among the various gamma-
herpesviruses tested (Table 2). These variations reflect the low-
level amino acid sequence homology (approximately 20% to
30%) between the TKs of gammaherpesviruses. Diversity in anti-
viral activities of TK-dependent drugs against EBV and KSHV
might also be a consequence of a poor TK activity of KSHV as
opposed to that of EBV. The low KSHV TK activity was previously
described based on the low incorporation of thymidine into DNA
(18). It remains to be elucidated whether MHV-68, HVS, and
RRV have similarly low TK activities.
Previously, the antiviral activities of deoxyuridine analogs
against EBV and KSHV were shown to be dependent on the sub-
stitution on the 5= position of the uracil, showing that the presence
of a halogen group, such as chloro, bromo, or iodo, in 5-substi-
tuted deoxyuridines increased affinity for the viral TK compared
to results with the methyl counterpart (18, 45). Here, we observed
that the inhibitory activities of 5-substitued deoxyuridines against
gammaherpesviruses are greatest when the halogen atom is sub-
stituted to bromovinyl, such as in BVDU. A substitution with iodo
was inhibitory only to EBV and MHV-68. Moreover, replacement
of the uracil by a cytosine [CVDU to (E)-CVDC] did not alter the
antiviral potency against gammaherpesviruses, with the exception
of HVS.
BVDU was the most active uridine analog against all tested
gammaherpesviruses in vitro; however, this drug failed to exert its
inhibitory effect in a mouse model of gammaherpesvirus infection
(14, 35). The lack of efficacy of BVDU in vivo may result from the
degradation of the drug by phosphorylases, converting it into
BVU, which is inactive as an antiviral agent (46). On the contrary,
(E)-CVDC and CVDU are resistant to degradation by these en-
zymes (36) and thus are expected to have a longer intracellular
half-life, which could lead to potentially higher efficacy when eval-
uated in vivo against gammaherpesvirus infections.
Modification of the sugar ring, e.g., ribose nucleoside configu-
ration of BVDU to an arabinose nucleoside conformation, as in
BVaraU, is associated with a loss of inhibitory activity against
rhadinoviruses but not against EBV. Introduction of fluorine on
the sugar ring gives the arabinose nucleoside analog FIAC, with
potency comparable to that seen for 5=-halogenated nucleoside
analogs (e.g., BVDU) against all gammaherpesviruses. The selec-
tivity of FIAC is probably partially dependent on virus TK, since
low levels of resistance to FIAC were seen with TK HVS and
MHV-68 mutants. Yet the commercial development of this com-
pound, once considered for the treatment of HCMV and hepatitis
B virus infections, is no longer pursued due to toxicity (47).
Six conserved regions have been identified among herpesvirus
TKs, including an ATP-binding site and a nucleoside-binding site.
In HVS mutants selected in vitro under pressure of BVDU, we
identified four different mutations in the viral TK, and they were
all substitutions resulting in an amino acid change or the insertion
of a stop codon, leading to the production of a truncated TK. A
double amount of passages was needed to select the BVDUr
MHV-68 TK mutant bearing the C372W substitution. How-
ever, the C372W change in MHV-68 TK conferred 10-fold less
resistance to BVDU compared to the BVDUr HVS TK mutants.
Yet both A398D and C372W are located in the active site of
viral TK.
ACVr MHV-68 acquired mutations in viral PK, whereas ACVr
HVS showed mutations predominantly in viral DNA polymerase
(although one clone had an additional mutation in viral PK). As
mentioned above, this might suggest that ACV is a better substrate
for MHV-68 PK than for HVS PK, explaining the high antiviral
activity of ACV against MHV-68. The data obtained with the
MHV-68 PK mutant that showed resistance to ACV (approxi-
mately 13-fold) and GCV (5-fold) is in line with the results re-
ported by Meng et al., who engineered EBV PK mutants contain-
ing stop codon insertions using a bacterial artificial chromosome
and demonstrated that PK was required for the activation of ACV
and GCV (21). It should be mentioned that no drug-associated
mutations were identified in viral TK, PK, and/or DNA polymer-
ase under pressure from GCV after 21 passages in cell culture for
HVS and 45 passages for MHV-68.
The ACVr HVS double mutant acquired an insertion of thymi-
dine in the substrate binding site of the viral PK, at a position
homologous to those of mutations mapped in HCMV pUL97
conferring GCV resistance (27, 31). The HVS mutant was resistant
to ACV and GCV; however, since it acquired another mutation in
the viral DNA polymerase, we could not assess the impact of the
PK mutation alone on the activation of ACV and GCV. Notably,
whereas the acquisition of GCVr in the HCMV strain consisted of
an in-frame deletion in pUL97 (31), the nucleotide insertion or
deletion identified in the HVS or MHV-68 mutants led to a frame-
shift and the production of a truncated PK.
Understanding the impact of each mutation at the molecular
level is hampered by the lack of a three-dimensional structure of
gammaherpesvirus TK and of the PK and DNA polymerases. Nev-
ertheless, the crystal structure of HSV-1 TK (PDB code 1KI8) and
DNA polymerases (PDB code 2GV9) can be used as putative mod-
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els, as depicted in Fig. 6. The substitutions here described (i.e.,
A398D and C372W) are located in the active site of the viral TK
and are expected to impair the activity of the enzyme. Other
amino acid changes (i.e., P326T, Q401R, E358D, and T364P) pre-
viously identified following selection with the novel pyrimidine
nucleoside derivative HDVD (35) are also located in the active site
of the viral TK. The E358D substitution is a minor change that
accounted for resistance to HDVD but not to BVDU. The model
of HSV-1 TK shows that the homologous glutamic acid at position
83 in HSV-1 is pointed toward the bromovinyl group of BVDU,
and the E83K substitution in HSV-1 TK is known to confer drug
resistance. This may explain why the substitution of glutamic acid
into aspartic acid (which has a shorter side chain and a smaller
volume [117 Å versus 140.1 Å] than glutamic acid) conferred re-
sistance to HDVD and not to BVDU.
The amino acid substitutions identified in the two ACVr HVS
clones, i.e., S529Y and L631I, are located in the conserved 
 region
C and region VI of the viral DNA polymerase, respectively (Fig. 5
and 6). The substitution L631I may induce a local structure
change in the finger domain of conserved region VI, which may
directly affect the interaction with incoming deoxynucleoside
triphosphates (dNTPs) or alter the interaction with other residues
involved in the formation of the polymerase active site (48, 49).
Although of the change from leucine to isoleucine may be a minor
change, it still affected the inhibitory activities of nucleoside ana-
logs (ACV and GCV), acyclic nucleoside phosphonates (HPMPC,
HPMP-5-azaC, PMEA, and PMEDAP), and PFA. In line with this,
the L782I substitution, also located in the conserved region VI of
the HSV-1 DNA polymerase, was previously characterized by pro-
ducing a recombinant HSV-1 mutant and was shown to confer
resistance to ACV (6-fold), HPMPC (2-fold), PMEA (4-fold), and
PFA (2-fold) (50).
The S529Y substitution in HVS DNA polymerase is located
in 
 region C, and mutations in this region of DNA poly-
merases of herpesviruses are known to affect the DNA poly-
merase activity and/or the 3=-to-5= exonuclease activity (50).
Nevertheless, the exact impact of this mutation on the antiviral
activity of ACV and GCV could not be evaluated because this
mutant also harbored a mutation in the viral PK. Yet, since a
substitution in the viral PK is not expected to affect the activity
of acyclic nucleoside phosphonates and PFA, changes in sus-
ceptibility to these drugs may be attributed to the effect of the
S529Y amino acid change in the viral DNA polymerase.
It is interesting to note that three point mutations found in the
TK and DNA polymerase of HVS occurred at conserved amino
acid positions in EBV and/or KSHV (Fig. 5). The alanine residue
at position 398 in the TK of HVS is conserved at a homologous
position in EBV. In the DNA polymerase, the serine at position
529 is conserved in both human gammaherpesviruses, while leu-
cine 631 is also found in KSHV. Reintroduction of the A398D
change in TK and/or of S529Y and L631I in the viral DNA poly-
merase in the genome of EBV and/or KSHV would be an interest-
ing approach in order to examine their effects on drug suscepti-
bilities toward EBV or KSHV.
Our findings highlighted the differences existing in sub-
strate recognition (pyrimidine versus purine analogs) among
the viral kinases (TK versus PK) of gammaherpesviruses.
Therefore, combinations of pyrimidine- and purine-based nu-
cleoside analogs should be investigated, since any synergistic
antiviral effects against gammaherpesviruses could potentiate
the impact of antiviral treatment. Additionally, this would de-
crease the likelihood of developing antiviral resistance in the
clinic if drug-associated mutations were to occur in EBV or
KSHV. At present, ACVr and/or GCVr EBV mutants have not
yet been described; nevertheless, Walling et al. provided evi-
dence for an ACVr EBV phenotype in a few immunocompro-
FIG 5 Sequence alignment of sites in HVS and MHV-68 TK and DNA polymerase in which drug resistance mutations occurred. The TK and DNA polymerase
sequences of the human herpesviruses (HSV-1, HSV-2, VZV, HCMV, EBV, and KSHV) belonging to three subfamilies (, , and ) were aligned. In addition,
three additional gammaherpesviruses, HVS, MHV-68, and RRV, were included. The two substitutions in the DNA polymerase gene occurred in the conserved
regions 
 region C and VI.
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mised patients with HIV-associated oral hairy leukoplakia
(51). Therefore, EBV PK and DNA polymerase should be ex-
amined when ACVr and GCVr are suspected.
Overall, we investigated for the first time the role of con-
served and nonconserved amino acids in TK, PK, and DNA
polymerase of MHV-68 and HVS through the selection of
drug-resistant viruses, regarding substrate recognition and vi-
rus drug sensitivity.
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